Tuesday, November 24, 2009, 4:11am EST - Canadian Markets open in 5 hours and 19 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Novogen Limited (NVGN)

 On Nov 23: 2.45 USD   0.00 (0.00%)  
MORE ON NVGN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Novogen Limited (NGM:NVGN) Delayed quote dataEdit
Last Trade: 2.45 USD
Trade Time: Nov 23
Change: 0.00 (0.00%)
Prev Close: 2.45
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: N/A
Day's Range: N/A - N/A
52wk Range: 1.23 - 7.00
Volume: 0
Avg Vol (3m): 24,212.3
Market Cap: 50.04M
P/E (ttm): N/A
EPS (ttm): -0.88
Div & Yield: N/A (N/A%)
Novogen Limited (NVGN)
1d  5d  3m  6m  1y  2y  5y  max 
 Add NVGN to Portfolio   Download Data

HEADLINES
• The Complete List of Australian ADR Stocks
at Seeking Alpha (Fri, Nov 6)
• Lee Enterprises, Novogen: Biggest Price Gainers (LEE, NVGN)
at The Wall Street Journal Online (Tue, Sep 29)
• Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo
Marketwire (Tue, Sep 29)
• Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
Marketwire (Tue, Sep 22)
• NOVOGEN LTD Financials
EDGAR Online Financials (Tue, Aug 18)
• Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
Marketwire (Wed, Aug 5)
• Novogen Director Retires
Marketwire (Thu, Jul 30)
• Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
Marketwire (Tue, Jul 7)
• Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
Marketwire (Wed, Jun 17)
• Novogen's NV-128 Targets the mTOR Pathway to Block Differentiation and Induce Cell Death in Ovarian Cancer Stem Cells
Marketwire (Mon, Apr 20)
• Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
Marketwire (Tue, Apr 14)
More Headlines for NVGN...
ANALYST
EPS Est (next year) (Dec-69) : N/A
EPS Est (in 2 years) (Dec-69) : N/A
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Novogen Limited and its subsidiaries engage in the research and development of pharmaceutical products, and marketing of consumer healthcare products. The company’s consumer healthcare products comprise Promensil, a range of natural products ...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices